|
May 18
|
Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 79%
|
|
May 17
|
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
|
|
May 17
|
Erasca restructures; Novartis moves to complete MorphoSys deal
|
|
May 17
|
BMS reports four-year data from psoriasis treatment extension trial
|
|
May 16
|
Walmart Earnings & the State of the Consumer
|
|
May 16
|
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
|
|
May 16
|
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
|
|
May 16
|
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
|
|
May 16
|
FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
|
|
May 16
|
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
|
|
May 15
|
UPDATE 2-US FDA approves expanded use of Bristol Myers' cancer cell therapy
|
|
May 13
|
These Stocks Moved the Most Today: GameStop, AMC, Arm, Squarespace, Walgreens, Tesla, Intel, Apple, and More
|
|
May 13
|
One stock is dragging down the S&P 500's earnings growth
|
|
May 13
|
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
|
|
May 13
|
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
|
|
May 13
|
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
|
|
May 12
|
Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip
|
|
May 11
|
Is Bristol Myers' Dividend in Danger?
|
|
May 10
|
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
|
|
May 10
|
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
|